Fortress Biotech (FBIO) CFO David Jin Receives 1,190 Shares

What Happened
David Jin, Chief Financial Officer of Fortress Biotech, reported an acquisition of 1,190 shares on 2026-10-01. The shares were acquired at $1.82 per share for a total of $2,165. The transaction is reported as an award/grant or other acquisition (code A) under the issuer's Employee Stock Purchase Plan.

Key Details

• Transaction date: 2026-10-01; Price: $1.82 per share; Shares acquired: 1,190; Total value: $2,165.
• Transaction type/code: A (award/other acquisition). Footnote indicates the acquisition was exempt under Rule 16b-3(d) and Rule 16b-3(c) as part of the company ESPP.
• Reported holdings: filing notes holdings include 1,230,000 shares underlying deferred restricted stock units and 400,000 shares underlying restricted stock units.
• Filing timeliness: Reported and filed on 2026-10-01 (no late filing indicated).

Context
This was a small purchase through the company’s employee plan—a routine, common-type transaction for insiders and often governed by plan rules. Restricted stock units (RSUs) referenced in the filing represent rights to future shares and are not necessarily currently tradable stock. The size of this purchase is modest and, by itself, should not be taken as a strong signal about management’s view of the company.